151 related articles for article (PubMed ID: 16736729)
1. Nalpha-methyl histamine safety and efficacy in migraine prophylaxis: phase III study.
Millán-Guerrero RO; Isais-Millán R; Benjamín TH; Tene CE
Can J Neurol Sci; 2006 May; 33(2):195-9. PubMed ID: 16736729
[TBL] [Abstract][Full Text] [Related]
2. Nalpha-methylhistamine safety and efficacy in migraine prophylaxis: phase I and phase II studies.
Millán-Guerrero RO; Pineda-Lucatero AG; Hernández-Benjamín T; Tene CE; Pacheco MF
Headache; 2003 Apr; 43(4):389-94. PubMed ID: 12656710
[TBL] [Abstract][Full Text] [Related]
3. Subcutaneous histamine versus botulinum toxin type A in migraine prophylaxis: a randomized, double-blind study.
Millán-Guerrero RO; Isais-Millán S; Barreto-Vizcaíno S; Rivera-Castaño L; Rios-Madariaga C
Eur J Neurol; 2009 Jan; 16(1):88-94. PubMed ID: 19087155
[TBL] [Abstract][Full Text] [Related]
4. Subcutaneous histamine versus topiramate in migraine prophylaxis: a double-blind study.
Millán-Guerrero RO; Isais-Millán R; Barreto-Vizcaíno S; Gutiérrez I; Rivera-Castaño L; Trujillo-Hernández B; Baltazar LM
Eur Neurol; 2008; 59(5):237-42. PubMed ID: 18264012
[TBL] [Abstract][Full Text] [Related]
5. N alpha methyl histamine versus propranolol in migraine prophylaxis.
Millán-Guerrero RO; Isais-Millán R; Guzmán-Chávez B; Castillo-Varela G
Can J Neurol Sci; 2014 Mar; 41(2):233-8. PubMed ID: 24534036
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous histamine versus sodium valproate in migraine prophylaxis: a randomized, controlled, double-blind study.
Millán-Guerrero RO; Isais-Millán R; Barreto-Vizcaíno S; Rivera-Castaño L; Garcia-Solorzano A; López-Blanca C; Membrila-Maldonado M; Muñoz-Solis R
Eur J Neurol; 2007 Oct; 14(10):1079-84. PubMed ID: 17880560
[TBL] [Abstract][Full Text] [Related]
7. Histamine as a therapeutic alternative in migraine prophylaxis: a randomized, placebo-controlled, double-blind study.
Guerrero RO; Cárdenas MA; Ocampo AA; Pacheco MF
Headache; 1999 Sep; 39(8):576-80. PubMed ID: 11279974
[TBL] [Abstract][Full Text] [Related]
8. [Subcutaneous histamine in migraine prophylaxis. Initial effects and long-term outcome].
Millán Guerrero R; Trujillo Hernández B; Tene CE
Neurologia; 2006 Mar; 21(2):55-9. PubMed ID: 16525910
[TBL] [Abstract][Full Text] [Related]
9. [New therapeutic alternatives in migraine prophylaxis using histamine H3 receptor agonists].
Millán-Guerrero RO; Isais-Millán R
Gac Med Mex; 2008; 144(4):291-5. PubMed ID: 18942262
[TBL] [Abstract][Full Text] [Related]
10. Histamine in migraine and brain.
Alstadhaug KB
Headache; 2014 Feb; 54(2):246-59. PubMed ID: 24433203
[TBL] [Abstract][Full Text] [Related]
11. A double-blind, randomized trial of low-dose topiramate vs propranolol in migraine prophylaxis.
Ashtari F; Shaygannejad V; Akbari M
Acta Neurol Scand; 2008 Nov; 118(5):301-5. PubMed ID: 18713156
[TBL] [Abstract][Full Text] [Related]
12. Histamine H3 receptor activation inhibits sympathetic-cholinergic responses in cats.
Koss MC
Eur J Pharmacol; 1994 May; 257(1-2):109-15. PubMed ID: 8082690
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Modified Wuzhuyu Decoction Granule ( ) for Migraine Patients with Cold and Stasis Obstructing Meridian Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial.
Liu HW; Zou YH; Cao KG; Yu LH; Zhang Y; Fu CH; Ma DY
Chin J Integr Med; 2018 Jun; 24(6):409-414. PubMed ID: 28741060
[TBL] [Abstract][Full Text] [Related]
14. Oxcarbazepine in migraine headache: a double-blind, randomized, placebo-controlled study.
Silberstein S; Saper J; Berenson F; Somogyi M; McCague K; D'Souza J
Neurology; 2008 Feb; 70(7):548-55. PubMed ID: 18268247
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular effects of R-alpha-methylhistamine, a selective histamine H3 receptor agonist, in rats: lack of involvement of histamine H3 receptors.
Hegde SS; Chan P; Eglen RM
Eur J Pharmacol; 1994 Jan; 251(1):43-51. PubMed ID: 7907986
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis--a double-blind, multicentre, randomized placebo-controlled dose-response study.
Pfaffenrath V; Diener HC; Fischer M; Friede M; Henneicke-von Zepelin HH;
Cephalalgia; 2002 Sep; 22(7):523-32. PubMed ID: 12230594
[TBL] [Abstract][Full Text] [Related]
17. Characterization of histamine-H3 receptors controlling non-adrenergic non-cholinergic contractions of the guinea-pig isolated ileum.
Taylor SJ; Kilpatrick GJ
Br J Pharmacol; 1992 Mar; 105(3):667-74. PubMed ID: 1352720
[TBL] [Abstract][Full Text] [Related]
18. Histamine H3 receptor activation potentiates peripheral opioid-mediated antinociception: substance P role in peripheral inflammation in mice.
Fernández-Dueñas V; Ciruela F; Gandía J; Sánchez S; Planas E; Poveda R
Eur J Pharmacol; 2010 Jul; 638(1-3):72-7. PubMed ID: 20435034
[TBL] [Abstract][Full Text] [Related]
19. Autoregulation of histamine release via the histamine H3 receptor on mast cells in the rat skin.
Ohkubo T; Shibata M; Inoue M; Kaya H; Takahashi H
Arch Int Pharmacodyn Ther; 1994; 328(3):307-14. PubMed ID: 7542864
[TBL] [Abstract][Full Text] [Related]
20. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study.
Diener HC; Bussone G; Van Oene JC; Lahaye M; Schwalen S; Goadsby PJ;
Cephalalgia; 2007 Jul; 27(7):814-23. PubMed ID: 17441971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
